A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke

Hany M Aref, Hala El-Khawas, Ahmed Elbassiouny, Hossam M Shokri, Mohamed G Zeinhom, Tamer M Roushdy, Hany M Aref, Hala El-Khawas, Ahmed Elbassiouny, Hossam M Shokri, Mohamed G Zeinhom, Tamer M Roushdy

Abstract

Background: Ticagrelor is one of the most recent antiplatelet drugs to be approved to treat ischemic heart disease. Its efficacy may exceed aspirin in improving clinical outcomes in patients with acute ischemic stroke who are ineligible for rt-PA.

Objectives: We evaluated the safety regarding hemorrhagic complications (as a primary endpoint) and the efficacy (as a secondary endpoint) of a 180-mg loading dose of ticagrelor given within 9 h from the onset of the first-ever non-cardioembolic ischemic stroke.

Methods: We conducted our study on patients aged 18-75 years who presented with their first clinically manifested non-cardioembolic ischemic stroke and were recruited from the emergency department OF Kafr El-Sheik University Hospitals, Egypt. Eligible patients randomly received ticagrelor or aspirin loading and maintenance doses. Screening, randomization, and initiation of treatment all occurred within the first 9 h of stroke onset.

Results: Eighty-five patients received ticagrelor, and 84 received aspirin. Patients who received ticagrelor had a better clinical outcome in terms of NIHSS improvement at 2 days and 1 week of discharge and a favorable mRS score after 1 week of discharge and at 90-day follow-up. There was no significant difference between the two groups regarding hemorrhagic adverse effects.

Conclusion: This pilot study found that ticagrelor had a better clinical outcome than aspirin based on NIHSS and mRS in acute ischemic stroke patients who received it within 9 h from symptom onset and had a shorter hospital stay duration. Ticagrelor was non-inferior to aspirin regarding hemorrhagic complications.

Trial registration: We registered our trial on ClinicalTrials.gov, named after "ticagrelor versus aspirin in ischemic stroke," and with a clinical trial number (NCT03884530)-March 21, 2019.

Keywords: Acute ischemic stroke; Egypt; Ticagrelor; Ticagrelor versus aspirin.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study flow diagram

References

    1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–1757. doi: 10.1016/S0140-6736(06)68770-9.
    1. Meyer DM, Albright KC, Allison TA, Grotta JC. LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. J Stroke Cerebrovasc Dis. 2008;17(1):26–29. doi: 10.1016/j.jstrokecerebrovasdis.2007.09.006.
    1. Jacobson KA, Boeynaems JM. P2Y nucleotide receptors: promise of therapeutic applications. Drug Discov Today. 2010;15(13–14):570–8. doi: 10.1016/j.drudis.2010.05.011.
    1. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Held P, et al. Acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes (SOCRATES) trial: rationale and design. Int J Stroke. 2015;10(8):1304–1308. doi: 10.1111/ijs.12610.
    1. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207–217. doi: 10.1056/NEJMoa1916870.
    1. Paciaroni M, Caso V, Agnelli G. The concept of ischemic penumbra in acute stroke and therapeutic opportunities. Eur Neurol. 2009;61(6):321–330. doi: 10.1159/000210544.
    1. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35–43. doi: 10.1056/NEJMoa1603060.
    1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American. Stroke A. 2019;50:344–418.
    1. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–438. doi: 10.1016/S1474-4422(13)70310-7.
    1. Ntaios G, Hart RG. Embolic stroke. Circulation. 2017;136(25):2403–2405. doi: 10.1161/CIRCULATIONAHA.117.030509.
    1. Hindricks G, Potpara T, Dagres N, Bax JJ, Boriani G, Dan GA, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612.
    1. Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202–204. doi: 10.1111/j.1538-7836.2009.03678.x.
    1. Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D et al (2011) New England J. 1317–29.
    1. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282. doi: 10.1016/S0140-6736(07)60149-4.
    1. Furlan AJ. Acute stroke trials: strengthening the underpowered. Stroke. 2002;33(6):1450–1451. doi: 10.1161/01.STR.0000018645.04200.7D.
    1. Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley EC, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke. 2000;31(10):2335–2341. doi: 10.1161/01.STR.31.10.2335.
    1. Wang Y, Minematsu K, Wong KSL, Amarenco P, Albers GW, Denison H, et al. Ticagrelor in acute stroke or transient ischemic attack in Asian patients. Stroke. 2017;48(1):167–173. doi: 10.1161/STROKEAHA.116.014891.
    1. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(4):301–10. doi: 10.1016/S1474-4422(17)30038-8.
    1. Van KF, Ciabattoni G, Patrono C, Schmitz PIM, Van GJ, Koudstaal PJ. Evidence for episodic platelet activation in acute ischemic stroke. Stroke. 1994;25(2):278–281. doi: 10.1161/01.STR.25.2.278.
    1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi: 10.1056/NEJMoa0904327.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren